I

IQVIA

Analytics, technology, and clinical research services.

Local Operations Manager - Sponsor Dedicated, Oncology

Full-TimeUpdated on 10/4/2026
$93.1k - $232.8k/yr+ Incentive plans + Bonus
Mid, Senior
Bachelor's
Durham, NC, USA
In Person
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A BA/BS degree in a health- or science-related field.
  • Three to five or more years of trial management experience, including independently managing complex clinical trials and leading country-level trial execution activities.
  • Oncology experience.
  • Strong working knowledge of ICH-GCP, Sponsor SOPs, local laws and regulations, assigned protocols, and associated protocol-specific procedures.
  • Strong IT skills in appropriate software and Sponsor systems.
  • Willingness to travel, including occasional overnight stays away from home, according to business needs.
  • Proficiency in speaking and writing the country language and English.
Responsibilities
  • Adhere to applicable Sponsor SOPs, work instructions, policies, Good Clinical Practice codes, and local regulatory requirements while serving as a subject matter expert and resource for quality and compliance standards across assigned studies.
  • Comply with relevant training requirements and maintain advanced therapeutic, operational, and regulatory knowledge applicable to assigned programs.
  • Lead and contribute to quality site selection by participating in site feasibility, ensuring consistent conduct of site qualification visits and appropriate follow-up of site qualification visit reports and country feasibility reports, and collaborating with central study teams and local stakeholders on site selection and performance optimization recommendations.
  • Ensure local or country teams meet recruitment targets with high-quality data, on time and within study budget, by providing strategic input to study-level documents and independently leading or coordinating local team activities in compliance with SOPs, procedural documents, and regulations. This may include developing local trial-specific procedures and tools, recruitment planning, contingency and risk management, budget forecasting, and mitigation strategies for complex studies.
  • Act as the primary Sponsor contact for assigned trials at the country level and serve as the local operational lead for complex studies. Participate in Investigator Meetings as needed and schedule and conduct local or country investigator meetings when appropriate.
  • Drive study compliance by maintaining and updating trial management systems, using available study tools and management reports to analyze trial progress, identifying risks, trends, and issues, initiating corrective and preventive actions when studies deviate from plans, and communicating progress, risks, mitigation strategies, and operational insights to study management and Quality & Compliance teams.
  • Lead the development and execution of country-level recruitment strategies and contingency planning with other functional areas to achieve clinical research targets and improve site performance.
  • Manage vendors at the country level, including overseeing vendor performance, resolving issues, managing budgets, reviewing and approving site and local vendor invoices as required, and submitting vendor-service requests or supporting vendor selection. Manage local study supplies as required.
  • Ensure high standards for study monitoring by leading quality local trial team meetings and facilitating Site Manager training when needed, including training on study amendments and changes in study-related processes.
  • Prepare country-specific informed consent documents in accordance with procedural documents and templates, and review and manage site-specific informed consent forms in accordance with SOPs, procedural documents, and applicable regulations.
  • Ensure adverse events, serious adverse events, and product quality complaints are reported within required timelines and documented appropriately; proactively identify and escalate potential patient safety concerns.
  • Ensure inspection readiness by maintaining complete, accurate, and timely data and essential documents in trial management systems, including CTMS and eTMF/IF, according to expectations and archiving requirements. Identify quality trends, compliance risks, and documentation gaps across projects, drive resolution, and timely escalate significant issues to the TDM/TDL and Sponsor.
  • Ensure sites provide accurate, valid, and complete data and resolve queries within expected timelines; provide oversight and guidance to improve site data quality and operational performance.
  • Maintain inspection readiness and current-work knowledge by complying with training requirements and maintaining advanced therapeutic-area, protocol, operational, and regulatory knowledge.
  • Work with Site Managers to ensure CAPAs are implemented for audits, inspections, and quality-related visits. Conduct accompanied site visits with Site Managers when delegated by the Sponsor and coach on quality-related findings and trends as needed.
  • Ensure accurate finance reporting and trial delivery within budget by meeting finance reporting deliverables and timelines, forecasting and managing country or local trial budgets, identifying financial risks, and implementing mitigation plans. Support negotiation of trial site contracts and budgets when applicable.
  • Ensure trial compliance with local regulatory requirements by organizing and securing IEC/HA approvals with the local Start-Up team, as applicable, and provide guidance on complex regulatory considerations and country-specific requirements.
  • Serve as a trainer, mentor, and subject matter expert for systems, processes, and local trial management practices; coach and support less experienced team members and contribute to onboarding and capability development.
  • Lead and contribute to functional-area initiatives, process improvements, inspection-readiness activities, operational excellence projects, and implementation of new systems and processes.
  • Submit time reporting accurately and on time.
  • Manage and start complex Early Phase trials and projects involving matrix clinical teams, external partners, and investigational sites, as applicable.
  • Lead country-level operational planning and execution for complex, high-priority, or high-risk studies requiring advanced trial management expertise and independent decision-making.
  • Complete region-specific deliverables when specified.

About the company

IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Get referred to IQVIA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 8.7%; management raised full-year revenue and EPS guidance.
  • R&DS bookings jumped 19.3% in Q2 2026, lifting backlog to $34.2 billion.
  • Nineteen of the top 20 pharma firms adopted IQVIA’s AI and analytics stack.

What critics are saying

  • Debt reached $15.999 billion on June 30, 2026; refinancing costs rose September 2026.
  • AbbVie, Pfizer, and peers can shift trials to Medpace, ICON, or internal platforms.
  • If AI claims disappoint regulators or clients, IQVIA’s premium multiples compress fast.

What makes IQVIA unique

  • IQVIA’s September 3, 2026 Predictive Clinical Development links data, AI, and trial operations.
  • Its Prime and Partner site network and proprietary healthcare data create sticky sponsor workflows.
  • The 2016 IMS Health merger gives IQVIA unmatched clinical, commercial, and real-world datasets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↓ -1%

2 year growth

↑ 0%
Diagnostics World News
Sep 24th, 2026
IQVIA MedTech introduces Surgical Collaboration Platform to help scale surgeon education.

IQVIA MedTech introduces Surgical Collaboration Platform to help scale surgeon education. IQVIA MedTech is highlighting its Surgical Collaboration Platform (SCP), a purpose-built platform designed to help MedTech organizations coordinate and track peer-to-peer surgeon education across the engagement lifecycle. As medical device companies introduce increasingly sophisticated devices, robotic systems, implants and surgical tools, clinician education can play a critical role in supporting technology adoption. However, the infrastructure behind these programs can remain fragmented, with education teams coordinating faculty availability, learner requests, scheduling, credentialing and documentation across spreadsheets, email and disconnected systems. The IQVIA MedTech Surgical Collaboration Platform is designed to bring those activities into a more connected workflow. The platform helps clinicians and education teams manage surgeon requests, credentialing, host-surgeon identification, faculty and site availability, scheduling, documentation, training completion and program reporting. The platform is intended to address an infrastructure challenge that can become increasingly complex as new technologies reach additional surgeons, sites and markets. By creating greater visibility across the education journey, IQVIA aims to help MedTech organizations more effectively coordinate and scale surgeon-to-surgeon education.

Yahoo Finance
Sep 16th, 2026
IQVIA stock surges 60% in 6 months on strong organic growth and AI adoption

IQVIA stock has risen 60.1% over the past six months, outpacing the industry's 4.1% return and the S&P 500's 14% rally. The company's strong performance is driven by accelerating organic growth, with second-quarter 2026 revenue rising 6% year over year. Research & Development Solutions grew 7% organically, whilst the commercial side increased 5%. IQVIA's R&DS net new bookings jumped 19.3% year over year in Q2 2026, producing a book-to-bill ratio of 1.22. Backlog reached $34.2 billion at the end of June. The company has deployed 294 AI agents across 90 use cases. Nineteen of the top 20 pharmaceutical companies have adopted IQVIA's solutions, strengthening its competitive position.

Jardal Paintball
Sep 9th, 2026
IQVIA prices $2B senior notes offering to refinance debt and credit facility

IQVIA Holdings announced its subsidiary IQVIA Inc. priced an offering of $2 billion in senior notes due 2034. The notes will bear interest at 6.375% per annum, with semi-annual payments beginning 15 March 2027, and mature on 15 March 2034. Proceeds will be used to redeem the company's senior 5.000% notes due 2026, repay part of its outstanding revolving credit facility debt, and cover offering fees and expenses. The issuance is expected to close on or about 23 September 2026, subject to customary conditions. IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries, employing approximately 94,000 people across over 100 countries.

Hyman, Phelps & McNamara, P.C.
Sep 4th, 2026
HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18).

HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18). September 4, 2026 Hyman, Phelps & McNamara, P.C.'s Karla Palmer and Andrew Hull will be speaking again at IQVIA's 28th Annual Controlled Substance & State Regulatory Conference in Scottsdale, AZ (Sept. 16-18). As part of a stacked agenda that runs the gamut on controlled substances issues, Ms. Palmer will speak on compliance considerations for compounders, and Mr. Hull will present on how registrants can mitigate risk and preserve reputation during a DEA investigation. Mr. Hull will also be presenting a course with retired DEA Chief Administrative Law Judge John J. Mulrooney, II, a partner at Belanger Rae & Mulrooney, on protecting your rights in DEA administrative actions. Join FDA Law Blog in Scottsdale for what promises to be another educational conference with key thought leaders and industry experts. Register here. Search FDA Law Blog. Subscribe. Never miss a post from FDA Law Blog

StockTitan
Sep 3rd, 2026
IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster.

IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster. IQVIA introduces an AI-driven clinical development platform that reports sizable time savings from study startup through data cleaning and between trial phases. (Positive) See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 09/03/2026 - 01:15 PM RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical Development is built to eliminate them, accelerating every stage of the development lifecycle with measurable results: * 33% faster study startup * 1.7 times more patients recruited from our AI prioritized and Prime & Partner sites with 42% higher enrollment rates * 50% faster data cleaning * 45%+ reduced time between trial phases IQVIA Predictive Clinical Development pairs IQVIA's proprietary data, deep regulatory expertise and best-in-class Healthcare-grade AI(R) with premier technologies from Anthropic, Amazon Web Services (AWS), Databricks, Microsoft, NVIDIA, Palantir and Snowflake orchestrated to drive agentic workflows. "At a time when every moment matters for patients waiting on new therapies, IQVIA Predictive Clinical Development represents a fundamental shift," said Richard Staub, president of Research and Development Solutions at IQVIA. "We're helping customers make development faster, more predictable and of a higher quality - compressing timelines, accelerating decisions and speeding medicines to market." IQVIA Predictive Clinical Development is enabled by IQVIA's clinical AI capabilities: * Clinical Design & Planning Suite generates predictive insights to inform site selection, prioritizes sites including its Prime and Partner network and operationalizes the recruitment strategy to speed enrollment. * Push Button Start-Up is an integrated and streamlined delivery model that applies standardization, automation and AI-enabled processes to accelerate the time to starting patient enrollment. * Real-time Data Cleaning enables faster, more reliable, higher quality data to make confident decisions during and after a study. It brings clinical data together across multiple sources, drives greater efficiency and enables more rapid database locks. IQVIA is uniquely positioned to change the trajectory of clinical development ultimately closing the gap between scientific discovery to patient care. As IQVIA extends its leadership in AI, new components will continue to expand Predictive Clinical Development across the entire development lifecycle, helping customers move faster with confidence. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Key terms. agentic workflows technical data cleaning technical database locks technical